Objectives: To describe the population PKs of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis (SLED).
Introduction
Sustained low-efficiency dialysis (SLED) is a form of prolonged intermittent renal replacement therapy (RRT) increasingly being used for critically ill patients.
1 SLED operates for 6-12 h/day and combines the advantages of intermittent haemodialysis leading to high solute removal with improved haemodynamic stability, which is similar to continuous RRT (CRRT). It is clear that the choice of the modality and the settings of RRT can significantly affect drug CL and alter dosing requirements. Blood and dialysate flow rates as well as filter types and surface areas have been shown to affect the PKs of various drugs. 2, 3 Despite the increasing and widespread use of SLED there is still a lack of SLED-specific dosing studies, making optimal anti-infective dosing a challenge for clinicians. 4 To date, there are few PK studies on antibiotics under SLED. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] To the best of our knowledge, there have been no studies published on the PKs and dosing requirements of ceftazidime during SLED. Moreover, a wide range of pathophysiological changes associated with sepsis may alter the PKs of antibiotics. [17] [18] [19] [20] Fluid resuscitation and the occurrence of capillary leakage influence the volume of distribution of many drugs. Knowledge of altered PKs to guide optimal anti-infective dosing is required to minimize infection-related mortality of septic critically ill patients, including those undergoing SLED. Ceftazidime is a commonly used cephalosporin in empirical and rational therapy in the ICU patients receiving SLED. Despite this, optimal dosing regimens remain undefined. Ceftazidime has a halflife of $1.5-2.5 h in patients with normal renal function, it has low protein binding ($17%) and is mainly excreted unchanged in the urine ($80-90%). 21, 22 With decreasing renal function, the half-life can increase to up to 15 h. 21, 22 Commonly, patients receiving SLED have little CL of renally cleared compounds during intermittent cessation of SLED, resulting in drug accumulation, but potentially higher CL during SLED sessions. As a b-lactam, ceftazidime has time-dependent bacterial killing capacities, which requires the serum concentration to be above the MIC for at least 50% of the dosing interval (50% fT .MIC ). 23 Recent studies recommend a more aggressive target of 100% fT .MIC for critically ill patients with severe infections. [24] [25] [26] To enable clinicians to prescribe a safe and effective dose of ceftazidime for critically ill septic patients on SLED, it is crucial to know the effects of SLED on its PKs.
Therefore, the aim of this study was to describe the population PKs of ceftazidime in critically ill septic patients receiving SLED. We also sought to perform Monte Carlo dosing simulations to develop recommendations for improved ceftazidime dosing regimens under SLED that may lead to adequate drug concentrations.
Patients and methods

Setting
This study was a single-arm, prospective, observational PK study sampling in 10 ICUs within a 1629 bed German university hospital between July 2013 and November 2014. The study was registered at clincialtrials.gov (see: NCT02287493).
Ethics
Ethics approval was obtained from the local Ethics Committee of the Hamburg Chamber of Physicians (approval reference number: PV4244) in April 2013. Written informed consent was obtained from each patient or their legal guardian.
Study population
The inclusion criteria were age !18 years and antibiotic treatment with ceftazidime in septic patients receiving SLED. Patients receiving SLED at night were excluded for logistics reasons.
Dosing, administration and data collection
Ceftazidime dosing was at the physician's discretion. Ceftazidime 1 or 2 g (Dr. Friedrich Eberth Arzneimittel GmbH, Germany) was diluted in 100 mL 0.9% sodium chloride and administered intravenously over 30 min every 8-12 h. Patients could have been treated with ceftazidime before inclusion in the study. Clinical and demographic data including vasopressor support and the requirement for mechanical ventilation were collected. Additionally, the SOFA score on the first day of sampling, the simplified acute physiology (SAPS II) score at ICU admission and length of ICU stay were recorded. Clinical parameters, e.g. serum creatinine concentration, residual diuresis, albumin, liver function, as well as C-reactive protein and procalcitonin were collected.
SLED
SLED was performed with the Genius V R batch system (Fresenius Medical Care, Bad Homburg, Germany) using a Fresenius FX 60 filter (surface area 1.4 m 2 ; Fresenius Medical Care). The biochemical composition of the dialysate was mixed based on the patient's biochemistry. SLED was performed according to the physicians order and did not correspond to the dosing regimen. SLED data such as blood flow and ultrafiltration rate as well as the duration of the session were recorded.
Sample collection
To determine serum ceftazidime concentrations, samples were taken from an indwelling arterial cannula on three consecutive days of SLED. As drug administration was set routinely to 06.00, 14.00 and 22.00 h, depending on a regimen of every 8 or 12 h, trough samples 1 h prior to infusion were followed by sampling 10 min and 1, 2 and 4 h after the start of SLED as well as at the end of the session. Starting SLED was dependent on availability and capacity and therefore variable. SLED started at 07.30 h but was no later than 10.00 h.
Sample handling, storage and measurement
Blood samples were centrifuged within 30 min at 3000 rpm, for 10 min. The serum supernatant was transferred to a tube and stored at -70 C until analysis. According to in-house stability tests and the literature, maximum time of storage was set to 3 months. 27 After protein precipitation samples were analysed by HPLC-UV. The method was validated and conducted in accordance with the guidelines of the US FDA guidance for industry on bioanalysis. 28 Intraday precision coefficients of variation were 2.9% for 8 mg/L, 1.1% for 16 mg/L and 1.9% for 64 mg/L. Interday precision coefficients of variation were ,15% for 8, 16 and 64 mg/L. Accuracy was.94% with a deviation of ,15% for all tested concentrations. The lower limit of quantitative detection was 0.8 mg/L.
Population PK modelling
One-and two-compartment models were developed with the Nonparametric Adaptive Grid algorithm within the Pmetrics V R package for R V R (Los Angeles, CA, USA). 29, 30 Lambda and Gamma error models were both tested for inclusion. Biologically plausible demographic and clinical characteristics for affecting ceftazidime PKs were tested for inclusion as covariates in a stepwise fashion. If the inclusion of a covariate resulted in an increase in the coefficient of determination of the linear regression (R 2 ) and in the reduction of the bias of the goodness-of-fit plots as well as in a statistically significant reduction in the log-likelihood (P , 0.05), the covariate was supported for inclusion.
Model diagnostics
The R 2 and the bias of the observed versus predicted plots as well as the log-likelihood of each run were taken into account for the goodness-of-fit evaluation. Predictive performance evaluation was based on mean prediction error (bias) and the mean bias-adjusted squared prediction error (imprecision) of the population and individual prediction models. Weighted residual plots versus time and concentration, as well as the visual predictive check plot and the normalized prediction distribution errors were also used to test the suitability of the final covariate model.
PTA
To determine the average PTA for the first 24 h of treatment, Monte Carlo simulation (n " 1000) of serum concentrations was performed using Pmetrics V R . We simulated for an 85 kg ICU patient receiving a 6 h SLED treatment between the administration of 0.5-2 g ceftazidime every 8 h and 1-2 g every 12 h with an infusion time of 30 min. Within the simulation, SLED started 17 h after the first dose of ceftazidime. Which means between the second and the third dose every 8 h and at the end of the dosage interval for an interval of every 12 h. The PTA against various MICs for the first König et al. 24 h, including a 6 h SLED session, accounted for the plasma protein binding of 17%. 31 The PD target was set to 50% fT .MIC according to the traditional target and 100% fT .MIC (concentrations above the MIC for 50/100% of the dosing interval). 23 This more aggressive target is considered reasonable for critically ill patients with severe infections. [24] [25] [26] Fractional target attainment calculation
The average fractional target attainment (FTA) was calculated by comparing the PD exposure, which is the PTA against an MIC distribution of certain bacteria. To determine the FTA we used MIC data of Pseudomonas aeruginosa from the EUCAST database (available at www.eucast.org, date accessed 10 January 2016). According to the general PD target we calculated the FTA by using 50% fT .MIC and 100% fT .MIC for a more aggressive treatment strategy. 23 For directed treatment of MIC values from 0.008 to 8 mg/L for susceptible strains (EUCAST) the FTA for achieving 50% and 100% fT .MIC was calculated from the Monte Carlo simulations (n " 1000). Additionally, the FTA for 50% and 100% fT .MIC for the whole P. aeruginosa population for empirical treatment was determined. We considered a dosing regimen as successful if it had.95% or.99% likelihood of FTA for susceptible strains.
Results
Demographic and clinical data
We measured 211 serum samples from 16 patients during the study period, with each patient having a median of three sets of six serum samples. The measured serum concentration of the cohort ranged from 11 mg/L to a maximum of 199 mg/L, with a median trough concentration of 80 mg/L (56-112). The study population was predominantly male (69%) with a median (IQR) age of 62.5 (55.5-66.5) years. Vasopressor therapy was required in 75% of the SLED patients and 75% were on invasive mechanical ventilation. Residual diuresis was 0 (0-90) mL/day and SLED was performed with a mean (SD) blood and dialysate flow of 264 mL/min (40) and a mean ultrafiltration of 540 mL/h (164) over 299 (68) min. The ICU mortality rate was 56% with 9 of 16 patients dying during their ICU stay. Further clinical and demographic data are shown in detail in Table 1 .
PK model building
A two-compartment linear model best described the concentration-time data of the total serum concentrations of ceftazidime. This model included zero order input into the central compartment. The two-compartment model showed a significantly (P " 0.008) better fit with a lower log-likelihood over the one-compartment model (1426 versus 1710), as well as a lower Akaike information criterion (AIC; 1438 versus 1718) and Bayesian information criterion (BIC; 1457 versus 1731). Additionally, the value for R 2 in the observed versus individual-predicted plot was higher for the two-compartment model (0.919 versus 0.668). The individual-predicted versus observed concentration plots for each patient was better with the two-compartment model.
Even though blood and dialysate flow as well as ultrafiltration were tested for inclusion in regard of CL on SLED, none of them resulted in a statistically significant improvement of the loglikelihood or the goodness-of-fit plots from the former model Pharmacokinetics of ceftazidime in patients receiving sustained low-efficiency dialysis JAC (P , 0.01). The volume of distribution of the central compartment and CL without SLED were allometrically scaled by weight (Wt) resulting in improvement of log-likelihood (1417 versus 1426), AIC (1429 versus 1438) and BIC (1448 versus 1457) compared to the two-compartment model. The gamma error model was used to best fit the data. Wt was included and the final model was described as follows:
CL 0 is the typical value of ceftazidime CL resulting from CL NON-SLED as the population parameter estimate of ceftazidime CL without SLED plus CL SLED as the population parameter estimate of ceftazidime CL with SLED. The term SLED becomes 1 when SLED is on whereas it is 0 when SLED is off. V c is the population parameter estimate of the central volume of distribution. Diagnostic plots such as the observed versus predicted plots, visual predictive check, weighted residuals ( Figure 1 ) and normalized prediction distribution errors (data not shown) were taken into account to confirm the goodness-of-fit of the chosen model. The mean (SD) population PK parameter estimates from the final model are displayed in Table 2 .
Dosing simulations
Monte Carlo simulations and the average PTA for achieving 50% and 100% fT .MIC for the first 24 h for various ceftazidime doses under a 6 h SLED session are described in Figures 2 and 3 . These plots describe that a dosing regimen of 1 g every 8 h for the traditional PD target of 50% fT .MIC achieved .95% PTA. Aiming for 100% fT .MIC a dosage of 2 g ceftazidime every 8-12 h with a PTA of 99% and 96%, is sufficient to cover strains with MIC up to 8 mg/L.
FTA
The average FTA for 50% and 100% fT .MIC for the first 24 h and a 6 h SLED session for a range of ceftazidime doses and dose frequencies against the susceptible MIC distribution for P. aeruginosa (28 318 isolates) are shown in Table 3 .
These data show that for susceptible P. aeruginosa strains with an MIC up to 8 mg/L a dose of 0.5 g ceftazidime every 8 h and 1 g every 12 h are able to achieve 50% fT .MIC for 98% and 99% of the susceptible isolates, respectively. Regarding the total population of P. aeruginosa (57 505 isolates), even a dosage of 2 g ceftazidime every 8 h, which was the most frequent dosage in our cohort, only covers 54% of all tested isolates. Aiming for 100% fT .MIC , a dosage of 1 g every 12 h and 2 g every 12 h are able to cover 96% and 99% of isolates with MIC 8 mg/L, respectively. However, a maximum dose of 2 g every 8 h only covers 52% of all tested isolates for 100% fT .MIC .
Discussion
Our study provides the first PK data for ceftazidime in critically ill septic patients receiving SLED. The present study shows that CL SLED and CL NON-SLED differ from each other and that overall ceftazidime CL varies during the course of the day. Therefore, a lower overall daily dosage during SLED may be sufficient to maintain target concentrations over time, depending on the chosen PK/PD target.
Previous literature has described that ceftazidime is cleared to various degrees depending on the mode of RRT. 22, 32 However, it is difficult to transfer PK data from studies on non-SLED RRT to the PK under SLED. Under continuous venovenous haemofiltration and continuous venovenous haemodialysis, ceftazidime CL was found to be 1.92 and 1.62 L/h, respectively. In our study CL SLED was substantially higher with a mean of 5.32 L/h (3.12). 3, 31 The higher CL of ceftazidime under SLED in comparison to CRRT can be explained by higher effluent and blood flow rates although adding flow rates for covariates on CL SLED did not improve the model fit. As this study was designed and performed during clinical practice we observed that blood and effluent rates are highly variable and not constant during the SLED session at our ICU. The high CL SLED for ceftazidime is similar to its CL under intermittent haemodialysis (6.8 L/h). 21 Moreover, ceftazidime CL during a 6 h SLED treatment almost corresponds to the CL recorded in healthy volunteers (6.0 L/h). 33 This highlights that SLED can effectively clear ceftazidime within a short period of time.
We found the CL NON-SLED of 1.06 L/h (0.59) to be slightly higher in comparison to 0.92 L/h (0.44) reported by Leroy et al. for patients with a CL CR ,15 mL/min. 21 This may be due to the fact that SLED is sometimes used to maintain or achieve fluid balance rather than for acute kidney injury.
The results show a higher mean central volume of distribution (V c ) of 14.56 L (10.53) for ceftazidime than recorded in healthy volunteers, being 8.89 L (1.61) for a 70 kg person. 21 This corresponds with other data on increased V c in critically ill patients. 20, 34, 35 The total bodyweight was included into the model as a covariate affecting V c , taking into account obesity in some of the study patients. However, the simulations showed no significant effect of V c on the CL of ceftazidime. Being on or off, SLED had the largest effect and impact on optimal ceftazidime dose and frequencies.
For cephalosporins an fT .MIC of $50% of the dosing interval is suggested for bactericidal activity. In our study ceftazidime concentrations exceeded the susceptibility breakpoint of 8 mg/L for P. aeruginosa for at least 50% of the dosing interval. A dosage regimen of 1 g ceftazidime every 8 h or 2 g every 12 h would be appropriate (PTA 98% and 99%, respectively) for the conventional target of 50% fT .MIC for MICs 8 mg/L. For the first day of treatment an initial loading dose of 2 g every 8 h should be considered.
Recent studies suggest to aim for a target of 100% fT .MIC particularly for critically ill septic patients. [24] [25] [26] Regarding the more aggressive target of 100% fT .MIC , a dosage of 2 g every 8-12 h was sufficient for isolates with MIC 8 mg/L. This dosage might be particularly important for patients with severe sepsis or septic shock at high risk of complications and death. Taking into account the MIC distribution for P. aeruginosa and a target of 100% fT .MIC a dose of 1 or 2 g every 12 h cover up to 96% and 99% of the susceptible isolates (MIC 8 mg/L), respectively. As CL SLED was found to be 5.32 L/h and CL NON-SLED 1.06 L/h those dosages are in accordance with common recommendations. They range between 2 g every 8 h for patients with normal renal function and 1-2 g 24 hourly for patient with renal impairment a CL CR ,1.8 L/h. 36 There are methodological limitations of this study. First, it was not possible to measure ceftazidime concentrations in the dialysate, the ultrafiltrate and the urine for technical and clinical reasons. Owing to the construction of the SLED device it was not König et al. Pharmacokinetics of ceftazidime in patients receiving sustained low-efficiency dialysis JAC possible to gain dialysate samples without stopping the machine. An interruption of the RRT was not in accordance with our ethics approval. Unfortunately, urine bags were disposed of during the night, when none of the study staff was available. Endogenous renal function could not be estimated because serum creatinine concentration is affected by previous SLED or CRRT sessions.
Additionally, post-SLED samples were not collected. Therefore, a potential rebound in serum concentrations as has been described for vancomycin could not have been characterized, even though this effect has not be shown for hydrophilic agents such as meropenem.
14 The population PK model only calculates the total ceftazidime CL during SLED. Additionally, only trough concentration before the start of SLED was sampled. Thus, CL NON-SLED is based on a rather small sample size and cannot differentiate between renal and non-renal CL. Furthermore, some patients were treated with a CRRT before switching to SLED, potentially carrying over effects of the previous RRT.
Secondly, the simulations in this present study only simulate for 6 h of SLED as this was the average duration of SLED in our department. Therefore, the dosing suggestions cannot be extrapolated to those patients receiving longer and more intensive RRT with SLED. The same applies for less effective procedures, e.g. discontinuing due to blood clotting in the filter or other interruptions.
Thirdly, simulated dosages are based on an MIC cut-off of 8 mg/L for susceptible P. aeruginosa strains and are therefore suitable for directed therapy. This dose may not be sufficient for more resistant strains with MIC .8 mg/L. Depending on the local microbiological relative resistances, optimal empirical dosing of ceftazidime is very difficult. Dual empirical antibiotic treatment is often considered in patients with severe sepsis combining ceftazidime with an additional antibiotic agent to broaden the coverage of the potential spectrum of pathogens.
Fourthly, the study was not powered to measure clinical outcomes, such as clinical cure or survival.
Conclusions
A dose of 1 g every 8 h during a daily 6 h session of SLED achieves the conventional PK target of 50% fT .MIC for pathogens with MIC up to 8 mg/L. Aiming for a higher PD target of 100% fT .MIC requires a dosage regimen of 2 g every 12 h. We observed a large overall interindividual PK variability, in particular the varying CL of . Average probability of target attainment (50% fT .MIC ) in the first 24 h with a 6 h SLED session between administration of various ceftazidime dosages. 
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